12/4
08:00 am
acon
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Medium
Report
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
12/2
08:00 am
acon
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Medium
Report
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
11/20
08:07 am
acon
Aclarion (NASDAQ:ACON) had its price target raised by analysts at Ascendiant Capital Markets from $22.00 to $23.00. They now have a "buy" rating on the stock.
Low
Report
Aclarion (NASDAQ:ACON) had its price target raised by analysts at Ascendiant Capital Markets from $22.00 to $23.00. They now have a "buy" rating on the stock.
11/5
06:00 am
acon
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
Low
Report
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
10/22
06:00 am
acon
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Low
Report
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
10/14
06:48 am
acon
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst [Yahoo! Finance]
Medium
Report
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst [Yahoo! Finance]
10/14
06:09 am
acon
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Medium
Report
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
10/13
06:11 am
acon
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference [Yahoo! Finance]
High
Report
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference [Yahoo! Finance]
10/13
06:00 am
acon
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
High
Report
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
10/7
06:09 am
acon
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH [Yahoo! Finance]
Medium
Report
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH [Yahoo! Finance]
10/7
06:00 am
acon
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Medium
Report
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
10/3
02:37 pm
acon
Aclarion (NASDAQ:ACON) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aclarion (NASDAQ:ACON) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
07:47 am
acon
Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers [Yahoo! Finance]
Low
Report
Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers [Yahoo! Finance]
10/1
07:17 am
acon
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
Low
Report
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
9/25
06:21 am
acon
First Patients Enrolled at UHealth – University of Miami in Aclarion's Pivotal CLARITY Trial [Yahoo! Finance]
Medium
Report
First Patients Enrolled at UHealth – University of Miami in Aclarion's Pivotal CLARITY Trial [Yahoo! Finance]
9/25
06:00 am
acon
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
Medium
Report
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
9/19
08:07 am
acon
Aclarion (NASDAQ:ACON) had its price target raised by analysts at Ascendiant Capital Markets from $20.00 to $22.00. They now have a "buy" rating on the stock.
Medium
Report
Aclarion (NASDAQ:ACON) had its price target raised by analysts at Ascendiant Capital Markets from $20.00 to $22.00. They now have a "buy" rating on the stock.